A trial to establish the efficacy and safety of budesonide/formoterol 160/4.5 mcg from a novel dry-powder inhaler (DPI) versus budesonide/formoterol 200/6 mcg from a DPI in adult and adolescent patients with persistent asthma
(
Zeitschriftenartikel
)